Provider Letters

/images/web_alerts.jpg

Provider communication becomes expeditious, electronic and eco-friendly

The Oklahoma Health Care Authority (OHCA) is pleased to announce its new “green” provider notification process. In going “green,” OHCA will offer providers the option of three sources of communication instead of the paper letter process. These options are:

  1. E-Mail Notification. Provider letters will be sent directly to the provider’s e-mail address.
  2. Web Alerts. A website banner on the OHCA secure site will notify providers of newly posted letters and include a link to the letters.

Providers: Please verify or update your contact information by logging in to the OHCA secure site and following these instructions:

  • Select “update provider file."
  • Verify your information; make corrections or changes as allowed.
  • Click the “submit” button.
   
 Search by Letter Number or Subject

Letter NumberSubjectDate Added to Web Site
2019-20 Prior Authorization of Medications Used to Treat Lymphoma9/17/2019
2019-19 New Out-of-State Services Rules and Supportive Processes9/10/2019
2019-18 Prior Authorization of Naglazyme (galsulfase) and Aldurazyme (laronidase)9/3/2019
2019-17 No PA Requirement for Psychiatric or Medical Detox Services Received in a Non-Psychiatric Unit of a Hospital9/9/2019
2019-16 Clarification of Laboratory Services Policy Changes8/13/2019
2019-15 Developmental Disabilities Services Updates7/31/2019
2019-14 ADvantage Program Updates7/31/2019
2019-13 Inpatient Behavioral Health Updates7/31/2019
2019-12 OHCA Program Updates7/31/2019
2019-11 OHCA Program Updates7/31/2019
2019-10 OHCA Program Updates7/31/2019
2019-09 OHCA Program Updates7/31/2019
2019-08 Prior Authorization Changes for Medication Assisted Treatment7/24/2019
2019-07 Provider Contract Backdating7/16/2019
2019-06 Change in Billing for Supprelin® LA5/29/2019
2019-05 PRTF post intervention debriefing requirements for members under the age of 215/10/2019
2019-04 A New Free Medication Management Program for SoonerCare Members on Multiple Medications4/10/2019
2019-03 Prior Authorization of Krystexxa® (pegloticase) and Signifor® LAR (pasireotide)2/4/2019
2019-02 Yearly Compliance with the Deficit Reduction Act of 20051/25/2019
2019-01 Laboratory and Diagnostic Testing1/25/2019
12345678910...